VIRALEZE™ to be launched with LloydsPharmacy in the UK

•  Starpharma has signed a sales and distribution agreement for VIRALEZE™ with LloydsPharmacy, one of the largest pharmacy groups in the UK
•  VIRALEZE™ will initially be available exclusively at LloydsPharmacy, one of the largest pharmacy chains in the UK with around 1,400 LloydsPharmacy stores across the UK
•  LloydsPharmacy is part of the global McKesson group, a leading international pharmaceutical wholesale and retail pharmacy company
•  McKesson UK is also one of the largest pharmaceutical wholesalers in the UK (via AAH), supplying over 14,000 independent UK pharmacies
•  The UK is the first country in Europe to launch VIRALEZE™, and Starpharma has a further European roll-out planned
•  VIRALEZE™ is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013) which is virucidal, irreversibly inactivating >99.9% of SARS-CoV-2 (the virus that causes COVID-19) within one minute
•  SPL7013 has been shown to be highly active against multiple strains of SARS-CoV-2 (the virus that causes COVID-19) as well as a broad spectrum of other viruses including influenza, RSV, SARS, MERS, and HIV

DISC: I hold

It will be interesting to see if this OTC ( over the counter...aka self administered ) product will be popular, especially with all the hype over injections

Starpharma signs DEP® ADC Research Agreement with MSD

Melbourne, Australia; 12 February 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.

Dr Jackie Fairley, CEO of Starpharma commented: “MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area.”

DEP® ADCs exploit the unique potential of Starpharma’s DEP® technology to provide enhanced characteristics to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. DEP® ADCs are the subject of internal and partnered programs.

Starpharma has previously demonstrated the significant advantages conveyed by DEP® ADCs in multiple preclinical studies, including its DEP® HER-2 ADC, which showed significant tumour regression and 100% survival, outperforming Herceptin & Kadcyla in a human ovarian cancer model. Starpharma’s DEP® technology has already yielded four clinical stage oncology products, including one under development by AstraZeneca.

DISC: I hold

AZD0466 clinical DEP® program global expansion

• AZD0466 clinical development program expanded to incorporate global clinical trial

• Clinical expansion facilitates patient recruitment into a global Phase 1 study in haematological tumours

• AZD0466 is a highly optimised nanomedicine formulation of AstraZeneca’s novel dual Bcl2/xL inhibitor which utilises Starpharma’s DEP® technology

Disc: I hold in Strawman & TRW

VIRALEZE COVID-19 nasal spray study to commence in January

 Starpharma has now received all necessary approvals to commence its study for VIRALEZE™ with enrolment to commence in early January 2021

 VIRALEZE™ expected to be ready for market in Q1 CY2021 with EU regulatory dossier >90% complete 

This study is being undertaken to support commercialisation activities for VIRALEZE™, and is not a requirement to achieve EU product registration. 

VIRALEZE™ contains SPL7013, a broad spectrum antiviral, which is the active in products approved in more than 40 countries

Disc: I hold in Strawman and ITRW